Biomarkers to enable early treatment of newborn brain injury

By |2026-03-25T08:03:30+00:00March 24th, 2026|

Biomarkers to enable early treatment of newborn brain injury

Lack of oxygen to the brain at birth affects almost 200 babies in Ireland each year and more than two million infants globally. This condition, known as hypoxic ischaemic encephalopathy (HIE), is a leading cause of newborn death and long-term neurological disability, including cerebral palsy.

Early diagnosis is critical, as treatments such as therapeutic hypothermia, or brain cooling as its often known, must be initiated within a narrow time window to reduce brain injury and improve outcomes. Yet identifying which babies will benefit from treatment remains a major clinical challenge.

Researchers at INFANT, working with collaborators at University College Cork and the Karolinska Institute in Sweden, identified and validated two blood-based biomarkers that can aid the early detection of birth-related brain injury. These biomarkers are microRNAs, small strands of genetic material found in umbilical cord blood, which were shown to be significantly reduced in newborns with HIE.

The research, led by INFANT Researcher, Professor Deirdre Murray, and involving umbilical cord blood samples from 170 newborn babies in Ireland and Sweden, demonstrated consistent biological patterns across populations, strengthening their potential clinical relevance.

As Professor Murray explains:

“Early diagnosis is critical in babies affected by hypoxic ischaemic encephalopathy. Our research shows consistent biological signals across different populations, which is a vital step towards identifying brain injury when treatment decisions matter most.”

By providing an early biological signal of injury, these biomarkers could support faster identification of infants who need urgent intervention and help guide transfer to specialist centres for brain cooling therapy.

INFANT Director Professor Geraldine Boylan highlights the broader significance of the work:

“This research demonstrates how sustained, collaborative effort can advance neonatal care. It reflects INFANT’s commitment to developing evidence that has real potential to improve outcomes for babies and families.”

Supported by funding from the Health Research Board and the National Children’s Research Centre, this research represents almost a decade of focused investigation into early brain injury. It is an important step towards improving diagnosis and care for newborns affected by HIE.

 

 

Predicting pre-eclampsia before it becomes dangerous

By |2026-03-25T08:04:00+00:00March 24th, 2026|

Predicting pre-eclampsia before it becomes dangerous

For many women, pre-eclampsia arrives without warning. What begins as a healthy pregnancy can suddenly become life-threatening, with serious consequences for both mother and baby. Despite affecting around 5% of first-time mothers, clinicians have had limited tools to predict who will develop the condition.

INFANT researchers aimed to change that uncertainty.

Using advanced metabolomic technologies, the team studied subtle changes in blood chemistry during pregnancy and identified a unique set of biomarkers linked to the later development of pre-eclampsia. These biomarkers make it possible to identify women at risk before clinical symptoms appear.

Early prediction changes everything. Women identified as high-risk can be monitored more closely, receive preventative treatments, and make informed decisions alongside their healthcare team. For clinicians, it enables targeted care rather than reactive treatment. For families, it offers something previously unavailable: time.

By shifting pre-eclampsia care from crisis response to early prevention, this research has the potential to save lives and reduce long-term complications for mothers and babies alike.

 

From research to real-time care: the ANSeR study

By |2026-03-25T10:54:51+00:00March 24th, 2026|

From research to real-time care: the ANSeR study

Babies admitted to neonatal intensive care due to complications during pregnancy are at high risk of brain injury and seizures, which can have lifelong consequences if not detected and treated early. Yet newborn seizures are notoriously difficult to identify, often showing no visible signs.

The ANSeR (Automated Neonatal Seizure Recognition) study was established to address this challenge. Led by Professor Gene Dempsey and Professor Geraldine Boylan and developed in collaboration with engineers at the INFANT Centre at University College Cork, the study focused on combining neonatal medicine, brain monitoring, and advanced algorithms to improve seizure detection.

Electroencephalogram (EEG) monitoring records a baby’s brain activity but interpreting these complex signals requires specialist expertise. This expertise however is not always available in neonatal units, particularly outside normal working hours. ANSeR was designed to act as an “EEG expert at the cot side”, available 24 hours a day.

Using algorithms trained to recognise seizure patterns, ANSeR continuously analyses brain activity and alerts clinical teams when seizures are detected. This enables faster intervention, more timely treatment, and better protection for the developing brain.

The ANSeR study demonstrates how interdisciplinary research at INFANT – bringing together clinicians, engineers, and data scientists – can translate directly into tools that improve care for vulnerable newborns and support clinical decision-making when it matters most.

 

 

Go to Top